乳腺癌分子医学专题 |
|
|
|
|
长链非编码RNA RP11-770J1.3和跨膜蛋白25对紫杉醇耐药人乳腺癌细胞株耐药性的影响 |
李钰1, 王月月1, 王海凤1, 张凌宇1, 丁勇兴2, 陈素莲3, 杨清玲3, 陈昌杰3 |
1. 蚌埠医学院临床检验诊断学实验中心, 安徽 蚌埠 233000;
2. 蚌埠市第三人民医院普外肿瘤科, 安徽 蚌埠 233000;
3. 蚌埠医学院生物化学与分子生物学教研室, 安徽 蚌埠 233000 |
|
Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells |
LI Yu1, WANG Yueyue1, WANG Haifeng1, ZHANG Lingyu1, DING Yongxing2, CHEN Sulian3, YANG Qingling3, CHEN Changjie3 |
1. Clinical Testing and Diagnose Experimental Center, Bengbu Medical College, Bengbu 233000, China;
2. Department of Oncology, the Third People's Hospital of Bengbu, Bengbu 233000, China;
3. Department of Biochemistry & Molecular Biology, Bengbu Medical College, Bengbu 233000, China |
引用本文:
李钰 等. 长链非编码RNA RP11-770J1.3和跨膜蛋白25对紫杉醇耐药人乳腺癌细胞株耐药性的影响[J]. 浙江大学学报(医学版), 2017, 46(4): 364-370.
LI Yu, WANG Yueyue, WANG Haifeng, ZHANG Lingyu, DING Yongxing, CHEN Sulian, YANG Qingling, CHEN Changjie. Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells. Journal of ZheJiang University(Medical Science), 2017, 46(4): 364-370.
链接本文:
http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2017.08.04
或
http://www.zjujournals.com/xueshu/med/CN/Y2017/V46/I4/364
|
[1] DESANTIS C, MA J, BRYAN L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin,2014,64(1):52-62.
[2] SAKAMOTO J, MATSUI T, KODERA Y. Paclitaxel chemotherapy for the treatment of gastric cancer[J]. Gastric Cancer,2009,12(2):69-78.
[3] FOJO T, MENEFEE M. Mechanisms of multidrug resistance:the potential role of microtubule-stabilizing agents[J]. Ann Oncol,2007,18 Suppl 5:v3-8.
[4] SI X, ZANG R, ZHANG E, et al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK[J]. Oncotarget,2016,7(49):81452-81462.
[5] LIU W, MA J, CHENG Y, et al. HMMR antisense RNA1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells[J]. Breast Cancer(Dove Med Press),2016,8(1):223-229.
[6] HRAŠOVEC S, HAUPTMAN N, GLAVAC D, et al. TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer[J]. Dis Markers,2013,34(2):93-104.
[7] DOOLAN P, CLYNES M, KENNEDY S, et al. TMEM25, REPS2 and Meis 1:favourable prognostic and predictive biomarkers for breast cancer[J]. Tumour Biol,2009,30(4):200-209.
[8] YANG Q L, HUANG J, WU Q, et al. Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells[J]. Br J Cancer,2014,110(8):1958-1967.
[9] DINIC J, PODOLSKI-RENIC A, STANKOVIC T, et al. New approaches with natural product drugs for overcoming multidrug resistance in cancer[J]. Curr Pharm Des,2015,21(38):5589-5604.
[10] TSANG W P, KWOK T T. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells[J]. Oncogene,2007,26(33):4877-4881.
[11] LIU H, WANG G, YANG L, et al. Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/β-Catenin pathway[J/OL]. PLoS One,2016,11(12):e0168406.
[12] YANG Y, JIANG Y, WAN Y, et al. UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis[J]. Tumour Biol,2016,37(8):10633-10641.
[13] LIU Y, XU N, LIU B, et al. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines[J]. Oncotarget,2016,7(28):43835-43851.
[14] DE VRIES N A, ZHAO J, KROON E, et al. P-glycoprotein and breast cancer resistance protein:two dominant transporters working together in limiting the brain penetration of topotecan[J]. Clin Cancer Res,2007,13(21):6440-6449.
[15] DIAH S K, SMITHERMAN P K, ALDRIDGE J, et al. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells:evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins[J]. Cancer Res,2001,61(14):5461-5467.
[16] NAGASHIMA S, SODA H, OKA M, et al. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer[J]. Cancer Chemother Pharmacol,2006,58(5):594-600.
[17] 易娟,陈静,孙静,等.白血病K562/ADM细胞耐药性与白血病干细胞及耐药蛋白表达的关系[J].中华医学杂志,2009,89(25):1741-1744. YI Juan, CHEN Jing, SUN Jing, et al.The relationship between multi-drug resistance and proportion of leukemia stem cells and expression of drug transporters in drug-resistant leukemia K562/ADM cells[J]. National Medical Journal of China,2009,89(25):1741-1744. (in Chinese)
[18] 赵遵兰,蔡颖,王洋洋,等.微小RNA-21对人乳腺癌细胞株紫杉醇耐药性的影响及其机制[J].浙江大学学报(医学版),2015,44(4):400-405. ZHAO Zunlan, CAI Yin, WANG Yangyang, et al. Effect of miRNA-21 on paclitaxel-resistance in human breast cancer cells[J]. Journal of Zhejiang University:Medical Sciences,2015,44(4):400-405. (in Chinese) |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|